853056-96-9

Usage

Uses

Used in Aroma Compounds and Fragrances:
(R)-N-METHOXY-N-METHYL-1-((S)-1-PHENYLETHYL)AZIRIDINE-2-CARBOXAMIDE is used as a synthetic building block for creating aroma compounds and fragrances. Its organoleptic properties make it a valuable component in the development of scents and flavors for various industries, including cosmetics, food, and beverages.
Used in Pharmaceutical Development:
In the pharmaceutical industry, (R)-N-METHOXY-N-METHYL-1-((S)-1-PHENYLETHYL)AZIRIDINE-2-CARBOXAMIDE is used as a starting material for the development of pharmaceutical products. Its unique chemical structure allows for the creation of new compounds with potential therapeutic applications.
Used as an Antineoplastic Agent:
(R)-N-METHOXY-N-METHYL-1-((S)-1-PHENYLETHYL)AZIRIDINE-2-CARBOXAMIDE is used as an antineoplastic agent for the treatment of tumors. Its potential therapeutic uses make it a promising candidate for further research and development in oncology, with the aim of improving cancer treatment options and patient outcomes.

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 397849-98-8 N-[(R)-(+)-α-methylbenzyl]aziridine-2-(S)-carboxylic acid menthyl ester 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 397849-98-8 N-[(R)-(+)-α-methylbenzyl]-2(S)-carboxylic acid (-)-menthol ester 
• 68820-72-4 (2S)-1-[(R)-α-methylbenzyl]-2-aziridinecarboxylate ethyl ester 

Downstream Products

• 884498-59-3 1-{(S)-1-[(R)-1-phenylethyl]aziridin-2-yl}hexadec-2-yn-1-one 
• 488834-94-2 (4-Chloro-phenyl)-[(S)-1-((R)-1-phenyl-ethyl)-aziridin-2-yl]-methanone 
• 867150-63-8 2-phenyl-1-((S)-1-((R)-1-phenylethyl)aziridine-2-yl)ethanone 
• 488834-87-3 (2S)-N-[(R)-α-methylbenzyl]aziridinyl phenyl ketone 
• 1234672-53-7 4-(tert-butyldimethylsilyloxy)-1-{(S)-1-[(R)-1-phenylethyl]aziridin-2-yl}butan-1-one 
• 1278521-97-3 1-{(S)-1-[(R)-1-phenylethyl]aziridin-2-yl}but-2-yn-1-one 
• 1278521-98-4 (S)-1-{(S)-1-[(R)-1-phenylethyl]aziridin-2-yl}but-2-yn-1-ol 
• 1278521-99-5 (R)-1-{(S)-1-[(R)-1-phenylethyl]aziridin-2-yl}but-2-yn-1-ol 
• 1278522-00-1 (S,E)-1-{(S)-1-[(R)-1-phenylethyl]aziridin-2-yl}but-2-en-1-ol 
• 1278522-01-2 (R,E)-1-{(S)-1-[(R)-1-phenylethyl]aziridin-2-yl}but-2-en-1-ol 
• 1278522-02-3 (S)-2-[(S,E)-1-(t-butyldimethylsilyloxy)but-2-enyl]-1-[(R)-1-phenylethyl]aziridine 
• 1278522-03-4 (S)-2-[(R,E)-1-(t-butyldimethylsilyloxy)but-2-enyl]-1-[(R)-1-phenylethyl]aziridine 
• 1278522-04-5 (2S,3S,E)-3-(t-butyldimethylsilyloxy)-2-[(R)-1-phenylethylamino]hex-4-enyl acetate 
• 1278522-05-6 (2S,3R,E)-3-(t-butyldimethylsilyloxy)-2-[(R)-1-phenylethylamino]hex-4-enyl acetate 

Relevant academic research and scientific papers

Structure and conserved function of iso-branched sphingoid bases from the nematode: Caenorhabditis elegans

Sphingolipids are bio-active metabolites that show structural diversity among eukaryotes. They are essential for growth of all eukaryotic cells but when produced in an uncontrolled manner can lead to cell death and pathologies including auto-immune reacti

Asymmetric synthesis of 1-deoxyazasugars from chiral aziridines

A general and facile synthesis of enantiopure 1-deoxyazasugars was achieved from stereoselective dihydroxylation of a common synthetic intermediate, piperidine ring fused oxazolidin-2-one, originating from a commercially available starting substrate, chiral aziridine-2-carboxylate, in high yields. The Royal Society of Chemistry 2011.

3,4-Disubstituted oxazolidin-2-ones as constrained ceramide analogs with anticancer activities

Heterocyclic analogs of ceramide as 3-alkanoyl or benzoyl-4-(1-hydroxy-2- enyl)-oxazolidin-2-ones were designed by binding of primary alcohol and amide in sphinogosine backbone as a carbamate. They were synthesized by addition of acyl halide to the common

A formal synthesis of (-)-swainsonine from a chiral aziridine

A formal synthesis of enantiomerically pure (-)-swainsonine was successfully achieved using intramolecular cyclization of the amino alcohol 4 which was derived from a readily available 1-(R)-α-methylbenzylaziridine-2-carboxylic acid (-)-menthol ester 6.

Synthesis of constrained ceramide analogs and their potent antileukemic activities

Constrained ceramide analogs were designed and synthesized by binding terminal alcohol and amine of ceramide with additional carbonyl functional group as 3-acetyl (3), 3-propionyl (4), 3-benzoyl (5), and 3-hexadecanoyl-4-(1- hydroxyhexadec-2-enyl)-oxazoli

SPHINGOLIPID DERIVATIVES AND THE COMPOSITION FOR ANTI-CANCER CONTAINING THE SAME

Disclosed are a novel sphingolipid derivative having a sphingosine kinase suppressing activity and a composition containing the same. When the newly synthesized sphingolipid derivative of the invention is used, it is possible to maintain concentrations of ceramide and sphingosine to be high by preventing ceramide and sphingosine from being phosphorylated due to sphingosine kinase since an activity of sphingosine kinase is suppressed. In addition, since the apoptosis is induced in a cancer cell by ceramide and sphingosine, it is possible to treat or prevent a cancer or disease related to the cancer. Further, it is possible to treat or prevent a hyper- proliferative disease such as cancer or proliferation-promoting activity of sphingosine kinase. Accordingly, the composition containing the same can be used as a composition for suppressing sphingosine kinase and a composition for treating or preventing a cancer or hyper-proliferative disease.

Synthesis and evaluation of sphingoid analogs as inhibitors of sphingosine kinases

Sphingosine 1-phosphate (S1P), a product of sphingosine kinases (SphK), mediates diverse biological processes such as cell differentiation, proliferation, motility, and apoptosis. In an effort to search and identify specific inhibitors of human SphK, the inhibitory effects of synthetic sphingoid analogs on kinase activity were examined. Among the analogs tested, we found two, SG12 and SG14, that have specific inhibitory effects on hSphK2. N,N-Dimethylsphingosine (DMS), a well-known SphK inhibitor, displayed inhibitory effects for both SphK1 and SphK2, as well as protein kinase C. In contrast, SG12 and SG14 exhibited selective inhibitory effects on hSphK2. Furthermore, SG14 did not affect PKC. In isolated platelets, SG14 blocked the conversion of sphingosine into sphingosine 1-phosphate significantly. This is the first report on the identification of a hSphK2-specific inhibitor, which may provide a useful tool for studying the biological functions of hSphK2.

Efficient synthesis of enantiomerically pure 2-acylaziridines: Facile syntheses of N-Boc-safingol, N-Boc-D-erythro-sphinganine, and N-Boc-spisulosine from a common intermediate

Various enantiomerically pure 2-acylaziridines were prepared efficiently from the corresponding aziridine-2-carboxylate via Weinreb's amide and the subsequent treatment of organometallic compounds. The carbonyl group of those 2-acylaziridines was stereose